Albert Borla, the CEO of Pfizer a major global pharmaceutical company believes a vaccine to prevent COVID-19 could be ready by the end of October.
Foreign media reported on Saturday that Pfizer, in collaboration with German and RNA company Biotech, is conducting clinical trials in the United States and Europe for the BNT-162 vaccine program to prevent COVID-19.
He made the remarks while attending a virtual program organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) this week.
'In the event that things work out positively and the stars are adjusted, we will have enough proof of security and viability for us to feel good, for the FDA (US Food and Drug Administration) to feel great, there will be sufficient proof and adequacy for the Medicines Agency.'
Speakers at the event included AstraZeneca CEO Pascal Surrett, GlaxoSmithKline chief Emma Walmsley, Johnson and Johnson's chief scientific officer Paul Stifles.
Each of these companies is working with their partners to develop a vaccine to prevent the disease.
While GSK has joined forces with Sonofi, AstraZeneca is supporting a vaccine being developed at Oxford University.
J&J is teaming up with the US Biomedical Advanced Research and Development Authority to build up its vaccine.
So far, more than 120 vaccines have been prescribed worldwide. Currently, there are vaccines for at least 10 candidates in clinical diagnosis and 115 candidates in pre-clinical diagnosis.
According to the WHO, it is important to evaluate as many vaccines as possible because we cannot estimate how viable they will be.
The WHO said that in order to increase the chances of success, it is necessary to test the candidates until all the vaccines of the candidates have failed.
Pfizer and Biotech's advancement program includes four vaccine candidates, each representing an alternate blend of mRNA format and target antigen.
The new design of the trial design allows for the simultaneous review of multiple MRNA candidates in order to identify the safest and possibly most effective candidate among the maximum number of volunteers, in a manner that is consistent with regulatory authorities. Provide real-time data exchange assistance. .
'As our unique and robust clinical study program continues, beginning in Europe and now in the United States, we look forward to moving forward rapidly and collaboratively with our partners in biotech and regulatory authorities to ensure that patients A safe and effective vaccine could be brought,' Burla said in a statement earlier this month.
'The short, less than the four-month time frame in which we've had the option to move from pre-clinical studies to human testing is uncommon and further our duty to our top tier assets, from labs to manufacturing and completion.' In the fight against Quad 19, he added.
In anticipation of a successful clinical development program, Pfizer and Biotech are working to increase productivity for global supply.
Pfizer said the expansion of the program should allow the production of millions of vaccine doses in 2020, which will increase to hundreds of millions in 2021.
Meanwhile, a Chinese-made COVID-19 vaccine is expected to be available by the end of this year, according to a report published in the Official Wicket Account of the Commission for Monitoring and Assets of Public Assets.
The vaccine, together developed by the Beijing Institute of Biological Products and China National Biotech Group Co. has completed Phase II testing and could be prepared for showcase in the not so distant future or ahead of schedule one year from now.
The production line for the vaccine will be completely disassembled and shut down in preparation for output starting Saturday and will have the capacity to fully produce 100 million to 120 million vaccines each year.
0 Comments